OCULAR DISEASE AND EARLY ONSET MYOPIA
Dr Jessica Mountford
Brian King Fellow &
Head of Functional Molecular Vision Group
Lions Eye Institute, Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | November 2024
Dr Jessica Mountford received her highly ranked PhD from Monash University, Melbourne, in 2012, in the field of biochemistry and clinical haematology. Her work investigating novel ways to prevent thrombosis, a leading cause of heart attack and stroke, led to a first author publication in Nature Communications.
Following this, Dr Mountford relocated to Perth and went on to complete two post-doctoral appointments at the University of Western Australia, where she began research on the comparative evolution of visual and non-visual opsin across species of vertebrate, from the primitive lamprey to human.
During this period Dr Mountford began researching novel genetic variants associated with myopia development. With Adjunct Research Fellow appointments held at La Trobe University in Melbourne, and the University of Western Australia, Dr Mountford is currently the 6th Brian King Fellow and the Head of the Functional Molecular Vision Group at the Lions Eye Institute in Perth where she researches both the genetic and environmental factors involved in the development of early-onset myopia.
Dr Mountford has successfully established Western Australia’s first and only ocular genetic screening platform using zebrafish and utilises this model to help elucidate some of the complex gene-environment interactions responsible for the development of myopia.
-
Clinical guidelines for diagnostics and early intervention in Primary Aldosteronism
Primary Aldosteronism (PA), or Conn Syndrome, is the most commonly under-diagnosed cause of high blood pressure affecting millions of people. Associate Professor Jun Yang’s goal is to facilitate the diagnosis of every case of PA and make treatment widely available to all communities including the disadvantaged.
-
Biostatistics in Clinical Trials
As a biostatistician working in research and clinical settings, Kate Francis plays a vital role in ensuring all projects adhere to best practice guidelines and are transparently reported. She has served as the lead statistician for the analysis of clinical trials across a broad range of subject areas, including neonatal resuscitation, BCG for allergy and infection, convulsive status epilepticus and her work has been published in the top journals such as The New England Journal of Medicine, JAMA, and The Lancet. Most recently she was awarded the 2025 Excellence in Trial Statistics Award for her work on the PLUSS trial.
-
Next generation nanomedicine and radiopharmaceuticals to treat cancer
Finding better ways of treating cancer, aside from finding a cure, aim to provide a better quality of life for those who suffer from it.
Professor Thurecht’s work focuses on nanomedicine and spans across the Australian Institute for Bioengineering and Nanotechnology and the Centre for Advanced Imaging, at the University of Queensland in Australia.
